MDXG on XNAS, Health Care, MiMedx Group, Inc, job postings
Measures activity, not value. Not investment advice.
Latest quarter revenue fell 45% to $62.3M and the stock is down 53% in a year.
BadTwelve month revenue fell 23% to $303.7M, with a $19.2M net loss
Written by AI from the data on this page, 22 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
Industry
Surgical & medical instruments & apparatus (Health Care)
expected around 24 Feb 2027 (an estimate: a year ago it reported on 25 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $62.3M, net loss $8.7M.
31 Dec 2021RevenueNet incomeNet losstallest bar $118.1M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
$62.3M
-$8.7M
30 Jun 2026
$64.4M
-$14.8M
31 Mar 2026
$59.0M
-$10.9M
31 Dec 2025
$118.1M
$15.2M
30 Sep 2025
$113.7M
$16.7M
30 Jun 2025
$98.6M
$9.6M
31 Mar 2025
$88.2M
$7.0M
31 Dec 2024
$92.9M
$7.4M
30 Sep 2024
$84.1M
$8.1M
30 Jun 2024
$87.2M
$17.6M
31 Mar 2024
$84.7M
$9.3M
31 Dec 2023
–
$53.5M
30 Sep 2023
$81.7M
$8.5M
30 Jun 2023
$81.3M
$1.2M
31 Mar 2023
$71.7M
-$5.0M
31 Dec 2022
$74.4M
-$414K
30 Sep 2022
$67.7M
-$8.4M
30 Jun 2022
$66.9M
-$10.9M
31 Mar 2022
$58.9M
-$10.5M
31 Dec 2021
$67.4M
$2.2M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
$303.7M
$393.4M
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
-23%
+13%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
-$19.2M
$40.8M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
-$0.13
$0.27
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
77.3%
82.0%
60.5%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
-8.3%
13.7%
-8.3%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
-6.3%
10.4%
-10.1%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
-8.5%
-26.3%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
–
–
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$120.8M
$142.1M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
–
$18.2M
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
–
-$123.9M
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
–
0.31
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
$1.45
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
loss
28.0
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
1.5
2.3
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
–
2.5
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
2.1
2.8
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Revenue growth iSales in the latest reported quarter compared with the same quarter a year earlier.
-45%
$62.3M vs $113.7M (quarter ended 30 Sep 2026)
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
-4.5%
214 13F filers vs 224
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
79%
115.2M shares held by 13F filers (30 Sep 2026) of 145.9M outstanding (22 Oct 2026)
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
6.1%
9.0M shares sold short (30 Oct 2026) of 145.9M outstanding (22 Oct 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
4.3
9.0M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
-3.2%
9.3M shares sold short in the report before, 9.0M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
49%
49% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 46%
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
$200K
4 quarters
News iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
7
7 articles in the last 7 days; its usual week has 0.5 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
–
7 articles in the last 7 days; its usual week has 0.5: fewer than one, so there is nothing to compare with.
Price $3.05 on 20 Nov 2026, -53% over 12 months (12-month range $3.05 to $7.25)
Sharp change
8-K and other filings
Lobbying filing
Insider net buying (open market). Insiders bought a net $0 in the last 12 months (the 12 months before: -$803K).H-1B/E-3 applications certified. H-1B/E-3 applications certified: 0 published in the last 12 months, -100% on the 12 months before.Revenue per quarter. Revenue $62.3M in the latest quarter, -45% on a year earlier.Capital spending per quarter. Capital spending $427K in the latest quarter, -36% on a year earlier.Institutional holders (13F filers). 214 13F filers reported holding it in the latest 13F quarter, -2.3% on a year earlier.Federal obligations. Federal obligations: $0 published in the last 12 months.Lobbying spend. Lobbying spend: $200K published in the last 12 months, 0% on the 12 months before.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: workers in warn layoff notices.
Quarter ended 31 Dec 2021: $67.4M, -1.7% on a year earlier; public on 1 Mar 2022
Quarter ended 31 Mar 2022: $58.9M, -1.8% on a year earlier; public on 4 May 2022
Quarter ended 30 Jun 2022: $66.9M, -1.9% on a year earlier; public on 3 Aug 2022
Quarter ended 30 Sep 2022: $67.7M, +7.3% on a year earlier; public on 3 Nov 2022
Quarter ended 31 Dec 2022: $74.4M, +10% on a year earlier; public on 1 Mar 2023
Quarter ended 31 Mar 2023: $71.7M, +22% on a year earlier; public on 3 May 2023
Quarter ended 30 Jun 2023: $81.3M, +21% on a year earlier; public on 2 Aug 2023
Quarter ended 30 Sep 2023: $81.7M, +21% on a year earlier; public on 31 Oct 2023
Quarter ended 31 Mar 2024: $84.7M, +18% on a year earlier; public on 1 May 2024
Quarter ended 30 Jun 2024: $87.2M, +7.3% on a year earlier; public on 1 Aug 2024
Quarter ended 30 Sep 2024: $84.1M, +2.9% on a year earlier; public on 31 Oct 2024
Quarter ended 31 Dec 2024: $92.9M; public on 27 Feb 2025
Quarter ended 31 Mar 2025: $88.2M, +4.1% on a year earlier; public on 1 May 2025
Quarter ended 30 Jun 2025: $98.6M, +13% on a year earlier; public on 31 Jul 2025
Quarter ended 30 Sep 2025: $113.7M, +35% on a year earlier; public on 30 Oct 2025
Quarter ended 31 Dec 2025: $118.1M, +27% on a year earlier; public on 26 Feb 2026
Quarter ended 31 Mar 2026: $59.0M, -33% on a year earlier; public on 30 Apr 2026
Quarter ended 30 Jun 2026: $64.4M, -35% on a year earlier; public on 30 Jul 2026
Quarter ended 30 Sep 2026: $62.3M, -45% on a year earlier; public on 29 Oct 2026
Capital spending per quarter
Quarter ended 31 Mar 2021: $1.9M; public on 4 May 2022
Quarter ended 30 Jun 2021: $405K; public on 3 Aug 2022
Quarter ended 30 Sep 2021: $547K; public on 3 Nov 2022
Quarter ended 31 Dec 2021: $325K; public on 29 Feb 2024
Quarter ended 31 Mar 2022: $118K, -94% on a year earlier; public on 4 May 2022
Quarter ended 30 Jun 2022: $380K, -6.2% on a year earlier; public on 3 Aug 2022
Quarter ended 30 Sep 2022: $349K, -36% on a year earlier; public on 3 Nov 2022
Quarter ended 31 Dec 2022: $667K, +105% on a year earlier; public on 29 Feb 2024
Quarter ended 31 Mar 2023: $633K, +436% on a year earlier; public on 3 May 2023
Quarter ended 30 Jun 2023: $299K, -21% on a year earlier; public on 2 Aug 2023
Quarter ended 30 Sep 2023: $628K, +80% on a year earlier; public on 31 Oct 2023
Quarter ended 31 Dec 2023: $427K, -36% on a year earlier; public on 29 Feb 2024
Institutional holders (13F filers)
31 Dec 2021 report: 136; public on 14 Feb 2022
31 Mar 2022 report: 139; public on 16 May 2022
30 Jun 2022 report: 145; public on 15 Aug 2022
30 Sep 2022 report: 131; public on 14 Nov 2022
31 Dec 2022 report: 138; public on 14 Feb 2023
31 Mar 2023 report: 154; public on 15 May 2023
30 Jun 2023 report: 166; public on 14 Aug 2023
30 Sep 2023 report: 173; public on 14 Nov 2023
31 Dec 2023 report: 189; public on 14 Feb 2024
31 Mar 2024 report: 195; public on 15 May 2024
30 Jun 2024 report: 189; public on 14 Aug 2024
30 Sep 2024 report: 185; public on 14 Nov 2024
31 Dec 2024 report: 207; public on 14 Feb 2025
31 Mar 2025 report: 209; public on 15 May 2025
30 Jun 2025 report: 206; public on 14 Aug 2025
30 Sep 2025 report: 219; public on 14 Nov 2025
31 Dec 2025 report: 222; public on 17 Feb 2026
31 Mar 2026 report: 232; public on 15 May 2026
30 Jun 2026 report: 224; public on 14 Aug 2026
30 Sep 2026 report: 214; public on 16 Nov 2026
Federal obligations
Month from 1 Jan 2022: -$1.0 published
Month from 1 Feb 2022: $0 published
Month from 1 Aug 2022: $22K published
Month from 1 Oct 2022: -$2K published
Month from 1 Dec 2022: -$720 published
Month from 1 Jan 2023: $20K published
Month from 1 Feb 2023: $67K published
Month from 1 Mar 2023: $740 published
Month from 1 Apr 2023: $10K published
Month from 1 Nov 2023: $2K published
Month from 1 Sep 2024: $15K published
Month from 1 Nov 2024: $10K published
Month from 1 Feb 2025: -$2K published
Lobbying spend
Quarter from 1 Jan 2022: $30K published
Quarter from 1 Apr 2022: $30K published
Quarter from 1 Jul 2022: $50K published
Quarter from 1 Oct 2022: $50K published
Quarter from 1 Jan 2023: $50K published
Quarter from 1 Apr 2023: $50K published
Quarter from 1 Jul 2023: $50K published
Quarter from 1 Oct 2023: $20K published
Quarter from 1 Jan 2024: $20K published
Quarter from 1 Apr 2024: $20K published
Quarter from 1 Jul 2024: $50K published
Quarter from 1 Oct 2024: $50K published
Quarter from 1 Jan 2025: $50K published
Quarter from 1 Apr 2025: $50K published
Quarter from 1 Jul 2025: $50K published
Quarter from 1 Oct 2025: $50K published
Quarter from 1 Jan 2026: $50K published
Quarter from 1 Apr 2026: $50K published
Quarter from 1 Jul 2026: $50K published
Quarter from 1 Oct 2026: $50K published
What is unusual now
Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is insider open-market selling (USD, Form 4) at $433K (10 Nov 2025), 3.5× its normal reading; higher than 85% of its own history.
Reported lobbying spend: $50K in Q3 2026, $50K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.
Date
Change
Lobbying firm
Issue
Source
15 Jul 2024
New
Armory Hill Advocates (Formerly Known As Rawlson Policy Group)for Mimedx
Legislation and regulations impacting the delivery of wound management care to Medicare patients.Medicare/Medicaid
Two or more unrelated kinds of records unusual within 30 days
26 Feb 2026confirmed
Confirmed across sources Filings + Financials and Short interest and volume
MiMedx(MDXG): reported revenue of $118.1M for the quarter ended 31 Dec 2025, 1.3× the same quarter last year, while it had 8.4M shares sold short in the 30 Apr 2026 report, 1.8× the same report last year. Two unrelated kinds of activity within 84 days.
Short interest and volume: Short interest spike, became public on 11 Feb 2026
Financials: Quarterly revenue change, became public on 26 Feb 2026
Short interest and volume: Short interest spike, became public on 26 Feb 2026
Short interest and volume: Short interest spike, became public on 11 Mar 2026
Short interest and volume: Short interest spike, became public on 11 Apr 2026
Short interest and volume: Short interest spike, became public on 25 Apr 2026
Financials: Quarterly revenue change, became public on 30 Apr 2026
Short interest and volume: Short interest spike, became public on 12 May 2026
The quarter ended 31 Dec 2025 against the 8 quarters before it.
this quarterearliernormal: $87.7MSee the evidence (8 changes)
Short interest and volume: Short interest spike became public on 11 Feb 2026
MiMedx had 7.1M shares sold short in the 30 Jan 2026 report, 1.8× the same report last year.
This period
7.1M (the 30 Jan 2026 report)
Normal report (median of 24 earlier)
4.8M
Typical spread (median absolute deviation)
274K
How far from its usual level
+4.9
Same report last year
3.9M
History used
2,954 days
the 30 Jan 2026 report24 earlier reportsnormal: 4.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Financials: Quarterly revenue change became public on 26 Feb 2026
MiMedx reported revenue of $118.1M for the quarter ended 31 Dec 2025, 1.3× the same quarter last year.
This period
$118.1M (the quarter ended 31 Dec 2025)
Normal quarter (median of 8 earlier)
$87.7M
Typical spread (median absolute deviation)
$3.3M
How far from its usual level
+3.5
Same quarter last year
$92.9M
History used
3,562 days
the quarter ended 31 Dec 20258 earlier quartersnormal: $87.7M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Short interest and volume: Short interest spike became public on 26 Feb 2026
MiMedx had 7.3M shares sold short in the 13 Feb 2026 report, 2.0× the same report last year.
This period
7.3M (the 13 Feb 2026 report)
Normal report (median of 24 earlier)
4.8M
Typical spread (median absolute deviation)
283K
How far from its usual level
+5.1
Same report last year
3.7M
History used
2,968 days
the 13 Feb 2026 report24 earlier reportsnormal: 4.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 11 Mar 2026
MiMedx had 6.7M shares sold short in the 27 Feb 2026 report, 1.6× the same report last year.
This period
6.7M (the 27 Feb 2026 report)
Normal report (median of 24 earlier)
4.9M
Typical spread (median absolute deviation)
295K
How far from its usual level
+3.7
Same report last year
4.1M
History used
2,982 days
the 27 Feb 2026 report24 earlier reportsnormal: 4.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 11 Apr 2026
MiMedx had 7.7M shares sold short in the 31 Mar 2026 report, 1.6× the same report last year.
This period
7.7M (the 31 Mar 2026 report)
Normal report (median of 24 earlier)
5.0M
Typical spread (median absolute deviation)
323K
How far from its usual level
+5.3
Same report last year
4.7M
History used
3,014 days
the 31 Mar 2026 report24 earlier reportsnormal: 5.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 Apr 2026
MiMedx had 7.4M shares sold short in the 15 Apr 2026 report, 1.5× the same report last year.
This period
7.4M (the 15 Apr 2026 report)
Normal report (median of 24 earlier)
5.0M
Typical spread (median absolute deviation)
334K
How far from its usual level
+4.9
Same report last year
4.8M
History used
3,029 days
the 15 Apr 2026 report24 earlier reportsnormal: 5.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Financials: Quarterly revenue change became public on 30 Apr 2026
MiMedx reported revenue of $59.0M for the quarter ended 31 Mar 2026, 33% below the same quarter last year.
This period
$59.0M (the quarter ended 31 Mar 2026)
Normal quarter (median of 8 earlier)
$90.6M
Typical spread (median absolute deviation)
$6.2M
How far from its usual level
-3.4
Same quarter last year
$88.2M
History used
3,652 days
the quarter ended 31 Mar 20268 earlier quartersnormal: $90.6M
Fires when the period is at least 3.0 robust standard deviations away from the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Short interest and volume: Short interest spike became public on 12 May 2026
MiMedx had 8.4M shares sold short in the 30 Apr 2026 report, 1.8× the same report last year.
This period
8.4M (the 30 Apr 2026 report)
Normal report (median of 24 earlier)
5.1M
Typical spread (median absolute deviation)
397K
How far from its usual level
+5.6
Same report last year
4.8M
History used
3,044 days
the 30 Apr 2026 report24 earlier reportsnormal: 5.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
16 Feb 2021confirmed
Confirmed across sources Institutional holdings and Lobbying
MiMedx(MDXG): lobbying on a new issue, while it saw 75 13F filers open a new position in the quarter ended 31 Dec 2020, against none in the same quarter last year. Two unrelated kinds of activity within 26 days.
Lobbying: Lobbying on a new issue, became public on 21 Jan 2021
Institutional holdings: Many funds opening a new position, became public on 16 Feb 2021
The quarter ended 31 Dec 2020 against the 8 quarters before it.
this quarterearliernormal: 1.5See the evidence (2 changes)
Lobbying: Lobbying on a new issue became public on 21 Jan 2021
MiMedx lobbying on a new issue.
New
['MMM']
Rule
only points whose every posting (and value revision) is at or before as_of
Field
issue_codes
Metric
lobbying.filings_count
Point id
12774282
Institutional holdings: Many funds opening a new position became public on 16 Feb 2021
MiMedx saw 75 13F filers open a new position in the quarter ended 31 Dec 2020, against none in the same quarter last year.
This period
75 (the quarter ended 31 Dec 2020)
Normal quarter (median of 8 earlier)
1.5
Typical spread (median absolute deviation)
1
How far from its usual level
+24.5
Same quarter last year
0
History used
2,649 days
the quarter ended 31 Dec 20208 earlier quartersnormal: 1.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
Timeline
Changes and notable records, by the date each became public
12 May 2026Short interest and volume change
had 8.4M shares sold short in the 30 Apr 2026 report, 1.8× the same report last year.
Same report last year: 4.8M; its normal report is 5.1M.
See the evidence
This period
8.4M (the 30 Apr 2026 report)
Normal report (median of 24 earlier)
5.1M
Typical spread (median absolute deviation)
397K
How far from its usual level
+5.6
Same report last year
4.8M
History used
3,044 days
the 30 Apr 2026 report24 earlier reportsnormal: 5.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
reported revenue of $59.0M for the quarter ended 31 Mar 2026, 33% below the same quarter last year.
Same quarter last year: $88.2M; its normal quarter is $90.6M.
See the evidence
This period
$59.0M (the quarter ended 31 Mar 2026)
Normal quarter (median of 8 earlier)
$90.6M
Typical spread (median absolute deviation)
$6.2M
How far from its usual level
-3.4
Same quarter last year
$88.2M
History used
3,652 days
the quarter ended 31 Mar 20268 earlier quartersnormal: $90.6M
Fires when the period is at least 3.0 robust standard deviations away from the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
had 7.4M shares sold short in the 15 Apr 2026 report, 1.5× the same report last year.
Same report last year: 4.8M; its normal report is 5.0M.
See the evidence
This period
7.4M (the 15 Apr 2026 report)
Normal report (median of 24 earlier)
5.0M
Typical spread (median absolute deviation)
334K
How far from its usual level
+4.9
Same report last year
4.8M
History used
3,029 days
the 15 Apr 2026 report24 earlier reportsnormal: 5.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 7.7M shares sold short in the 31 Mar 2026 report, 1.6× the same report last year.
Same report last year: 4.7M; its normal report is 5.0M.
See the evidence
This period
7.7M (the 31 Mar 2026 report)
Normal report (median of 24 earlier)
5.0M
Typical spread (median absolute deviation)
323K
How far from its usual level
+5.3
Same report last year
4.7M
History used
3,014 days
the 31 Mar 2026 report24 earlier reportsnormal: 5.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 6.7M shares sold short in the 27 Feb 2026 report, 1.6× the same report last year.
Same report last year: 4.1M; its normal report is 4.9M.
See the evidence
This period
6.7M (the 27 Feb 2026 report)
Normal report (median of 24 earlier)
4.9M
Typical spread (median absolute deviation)
295K
How far from its usual level
+3.7
Same report last year
4.1M
History used
2,982 days
the 27 Feb 2026 report24 earlier reportsnormal: 4.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
reported revenue of $118.1M for the quarter ended 31 Dec 2025, 1.3× the same quarter last year, while it had 8.4M shares sold short in the 30 Apr 2026 report, 1.8× the same report last year. Two unrelated kinds of activity within 84 days.
See the evidence (8 changes)
Short interest and volume: Short interest spike became public on 11 Feb 2026
MiMedx had 7.1M shares sold short in the 30 Jan 2026 report, 1.8× the same report last year.
This period
7.1M (the 30 Jan 2026 report)
Normal report (median of 24 earlier)
4.8M
Typical spread (median absolute deviation)
274K
How far from its usual level
+4.9
Same report last year
3.9M
History used
2,954 days
the 30 Jan 2026 report24 earlier reportsnormal: 4.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Financials: Quarterly revenue change became public on 26 Feb 2026
MiMedx reported revenue of $118.1M for the quarter ended 31 Dec 2025, 1.3× the same quarter last year.
This period
$118.1M (the quarter ended 31 Dec 2025)
Normal quarter (median of 8 earlier)
$87.7M
Typical spread (median absolute deviation)
$3.3M
How far from its usual level
+3.5
Same quarter last year
$92.9M
History used
3,562 days
the quarter ended 31 Dec 20258 earlier quartersnormal: $87.7M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Short interest and volume: Short interest spike became public on 26 Feb 2026
MiMedx had 7.3M shares sold short in the 13 Feb 2026 report, 2.0× the same report last year.
This period
7.3M (the 13 Feb 2026 report)
Normal report (median of 24 earlier)
4.8M
Typical spread (median absolute deviation)
283K
How far from its usual level
+5.1
Same report last year
3.7M
History used
2,968 days
the 13 Feb 2026 report24 earlier reportsnormal: 4.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 11 Mar 2026
MiMedx had 6.7M shares sold short in the 27 Feb 2026 report, 1.6× the same report last year.
This period
6.7M (the 27 Feb 2026 report)
Normal report (median of 24 earlier)
4.9M
Typical spread (median absolute deviation)
295K
How far from its usual level
+3.7
Same report last year
4.1M
History used
2,982 days
the 27 Feb 2026 report24 earlier reportsnormal: 4.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 11 Apr 2026
MiMedx had 7.7M shares sold short in the 31 Mar 2026 report, 1.6× the same report last year.
This period
7.7M (the 31 Mar 2026 report)
Normal report (median of 24 earlier)
5.0M
Typical spread (median absolute deviation)
323K
How far from its usual level
+5.3
Same report last year
4.7M
History used
3,014 days
the 31 Mar 2026 report24 earlier reportsnormal: 5.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 Apr 2026
MiMedx had 7.4M shares sold short in the 15 Apr 2026 report, 1.5× the same report last year.
This period
7.4M (the 15 Apr 2026 report)
Normal report (median of 24 earlier)
5.0M
Typical spread (median absolute deviation)
334K
How far from its usual level
+4.9
Same report last year
4.8M
History used
3,029 days
the 15 Apr 2026 report24 earlier reportsnormal: 5.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Financials: Quarterly revenue change became public on 30 Apr 2026
MiMedx reported revenue of $59.0M for the quarter ended 31 Mar 2026, 33% below the same quarter last year.
This period
$59.0M (the quarter ended 31 Mar 2026)
Normal quarter (median of 8 earlier)
$90.6M
Typical spread (median absolute deviation)
$6.2M
How far from its usual level
-3.4
Same quarter last year
$88.2M
History used
3,652 days
the quarter ended 31 Mar 20268 earlier quartersnormal: $90.6M
Fires when the period is at least 3.0 robust standard deviations away from the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Short interest and volume: Short interest spike became public on 12 May 2026
MiMedx had 8.4M shares sold short in the 30 Apr 2026 report, 1.8× the same report last year.
This period
8.4M (the 30 Apr 2026 report)
Normal report (median of 24 earlier)
5.1M
Typical spread (median absolute deviation)
397K
How far from its usual level
+5.6
Same report last year
4.8M
History used
3,044 days
the 30 Apr 2026 report24 earlier reportsnormal: 5.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
26 Feb 2026Short interest and volume change
had 7.3M shares sold short in the 13 Feb 2026 report, 2.0× the same report last year.
Same report last year: 3.7M; its normal report is 4.8M.
See the evidence
This period
7.3M (the 13 Feb 2026 report)
Normal report (median of 24 earlier)
4.8M
Typical spread (median absolute deviation)
283K
How far from its usual level
+5.1
Same report last year
3.7M
History used
2,968 days
the 13 Feb 2026 report24 earlier reportsnormal: 4.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
reported revenue of $118.1M for the quarter ended 31 Dec 2025, 1.3× the same quarter last year.
Same quarter last year: $92.9M; its normal quarter is $87.7M.
See the evidence
This period
$118.1M (the quarter ended 31 Dec 2025)
Normal quarter (median of 8 earlier)
$87.7M
Typical spread (median absolute deviation)
$3.3M
How far from its usual level
+3.5
Same quarter last year
$92.9M
History used
3,562 days
the quarter ended 31 Dec 20258 earlier quartersnormal: $87.7M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
had 7.1M shares sold short in the 30 Jan 2026 report, 1.8× the same report last year.
Same report last year: 3.9M; its normal report is 4.8M.
See the evidence
This period
7.1M (the 30 Jan 2026 report)
Normal report (median of 24 earlier)
4.8M
Typical spread (median absolute deviation)
274K
How far from its usual level
+4.9
Same report last year
3.9M
History used
2,954 days
the 30 Jan 2026 report24 earlier reportsnormal: 4.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
reported revenue of $113.7M for the quarter ended 30 Sep 2025, 1.4× the same quarter last year.
Same quarter last year: $84.1M; its normal quarter is $87.0M.
See the evidence
This period
$113.7M (the quarter ended 30 Sep 2025)
Normal quarter (median of 8 earlier)
$87.0M
Typical spread (median absolute deviation)
$2.6M
How far from its usual level
+3.1
Same quarter last year
$84.1M
History used
3,470 days
the quarter ended 30 Sep 20258 earlier quartersnormal: $87.0M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
had 5.5M shares sold short in the 15 Mar 2024 report, 1.7× the same report last year.
Same report last year: 3.3M; its normal report is 3.5M.
See the evidence
This period
5.5M (the 15 Mar 2024 report)
Normal report (median of 24 earlier)
3.5M
Typical spread (median absolute deviation)
353K
How far from its usual level
+3.8
Same report last year
3.3M
History used
2,268 days
the 15 Mar 2024 report24 earlier reportsnormal: 3.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 5.3M shares sold short in the 29 Feb 2024 report, 1.7× the same report last year.
Same report last year: 3.2M; its normal report is 3.5M.
See the evidence
This period
5.3M (the 29 Feb 2024 report)
Normal report (median of 24 earlier)
3.5M
Typical spread (median absolute deviation)
292K
How far from its usual level
+4.2
Same report last year
3.2M
History used
2,253 days
the 29 Feb 2024 report24 earlier reportsnormal: 3.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 4.9M shares sold short in the 15 Feb 2024 report, 1.6× the same report last year.
Same report last year: 3.1M; its normal report is 3.4M.
See the evidence
This period
4.9M (the 15 Feb 2024 report)
Normal report (median of 24 earlier)
3.4M
Typical spread (median absolute deviation)
243K
How far from its usual level
+4.0
Same report last year
3.1M
History used
2,239 days
the 15 Feb 2024 report24 earlier reportsnormal: 3.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 4.7M shares sold short in the 31 Oct 2023 report, 1.3× the same report last year.
Same report last year: 3.7M; its normal report is 3.3M.
See the evidence
This period
4.7M (the 31 Oct 2023 report)
Normal report (median of 24 earlier)
3.3M
Typical spread (median absolute deviation)
162K
How far from its usual level
+4.0
Same report last year
3.7M
History used
2,132 days
the 31 Oct 2023 report24 earlier reportsnormal: 3.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 4.7M shares sold short in the 13 Oct 2023 report, 1.2× the same report last year.
Same report last year: 3.8M; its normal report is 3.3M.
See the evidence
This period
4.7M (the 13 Oct 2023 report)
Normal report (median of 24 earlier)
3.3M
Typical spread (median absolute deviation)
162K
How far from its usual level
+4.1
Same report last year
3.8M
History used
2,114 days
the 13 Oct 2023 report24 earlier reportsnormal: 3.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 4.6M shares sold short in the 29 Sep 2023 report, 1.1× the same report last year.
Same report last year: 4.0M; its normal report is 3.3M.
See the evidence
This period
4.6M (the 29 Sep 2023 report)
Normal report (median of 24 earlier)
3.3M
Typical spread (median absolute deviation)
162K
How far from its usual level
+3.9
Same report last year
4.0M
History used
2,100 days
the 29 Sep 2023 report24 earlier reportsnormal: 3.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
saw 27 13F filers open a new position in the quarter ended 30 Sep 2021, 14× the same quarter last year.
Same quarter last year: 2; its normal quarter is 2.5.
See the evidence
This period
27 (the quarter ended 30 Sep 2021)
Normal quarter (median of 8 earlier)
2.5
Typical spread (median absolute deviation)
2
How far from its usual level
+8.2
Same quarter last year
2
History used
2,922 days
the quarter ended 30 Sep 20218 earlier quartersnormal: 2.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
saw 42 13F filers open a new position in the quarter ended 30 Jun 2021, 42× the same quarter last year.
Same quarter last year: 1; its normal quarter is 2.
See the evidence
This period
42 (the quarter ended 30 Jun 2021)
Normal quarter (median of 8 earlier)
2
Typical spread (median absolute deviation)
1.5
How far from its usual level
+13.3
Same quarter last year
1
History used
2,830 days
the quarter ended 30 Jun 20218 earlier quartersnormal: 2
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Showing the newest 40 of 104 entries; narrow the window or the kind of data to see older ones.
Not listed: 198 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0001376339
Ticker
MDXG
Domain
mimedx.com
Employer name
MiMedx Group, Inc. (1 unverified)
Hq location
GA|MARIETTA|30062 (1 unverified)
Lobbying client
mimedx, mimedx group
Name
Alynx, Co., Company, MiMedx Group, Inc, MiMedx Japan, Godo Kaisha and 3 more
Uei
LHMTCHSJTFL3
Wikipedia
MiMedx
DOL H-1B labor condition applications and PERM certifications25 data points14 Jun 2021 to 7 Apr 2025
Federal lobbying disclosures (LDA)4 records, 96 data points2 Sep 2013 to 30 Sep 2026
SEC Form 13F institutional holdings481 data points30 Jun 2013 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)197 records11 Jan 2016 to 28 Oct 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)1027 data points31 Dec 2009 to 22 Oct 2026
SEC Form 4 insider transactions72 records, 192 data points12 May 2016 to 10 Nov 2025
FINRA short interest (twice monthly)624 data points29 Dec 2017 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)3178 data points1 Aug 2018 to 20 Nov 2026
USASpending.gov federal awards1746 data points14 Mar 2011 to 12 Feb 2025
Wikipedia pageviews11 data points11 Nov 2026 to 21 Nov 2026